John Strickler News Today

John Strickler, MD, introduces a panel of medical experts who will provide key insights for considerations in the 3L colorectal cancer treatment setting.

Derrick Cameron had a vision of savoring the sun, riding his motorcycle, and spending more time with his family when he retired from the Georgia Depar

The FDA has approved Tukysa (tucatinib) plus trastuzumab for adults with previously treated, RAS wild-type, HER2+ colorectal cancer.

The combination of HER2-targeted agents is already approved for use in breast cancer and is now is the first treatment approved for HER2-positive colorectal cancer.

The FDA has approved Tukysa (tucatinib) plus trastuzumab for adults with previously treated RAS wild-type, HER2-positive metastatic colorectal cancer.

Amgen Inc. (NASDAQ:NASDAQ:AMGN) European Society for Medical Oncology Annual Congress 2022 Conference Call September 12, 2022 01:30 PM ET Company Participants David Reese - Executive Vice...

Seagen recently presented positive pivotal Phase II data from its trial of Tukysa (tucatinib) in combination with trastuzumab in HER2-positive metastatic colorectal cancer.

Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance. 

The MTB expansion will initially focus on patients with lung and thyroid cancers in several rural counties in North Carolina.

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...